GeoVax Labs (GOVX) Registration filing summary

Company overview and business model

• Clinical-stage biotech focused on vaccines and immunotherapies for infectious diseases and solid tumors using proprietary platforms.

• Lead programs include GEO-MVA (mpox/smallpox vaccine), Gedeptin® (solid tumor therapy), and GEO-CM04S1 (multi-antigen COVID-19 vaccine).

• Strategy centers on advancing products through clinical trials and seeking partnerships or licensing for commercialization.

• Collaborates with government, academic, and corporate partners for development and validation.

Financial performance and metrics

• No product revenue to date; revenue derived from government grants and collaborations.

• Net loss of $21.5 million for the year ended December 31, 2025.

• Research and development expenses were $18.1 million in 2025, down 24% from 2024 due to contract terminations and lower clinical costs.

• Cash and cash equivalents as of December 31, 2025, were $3.1 million; sufficient to fund operations into mid-Q2 2026.

• Received a going concern opinion from auditors due to recurring losses and need for additional funding.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of shares by selling stockholders; proceeds from any cash exercise of warrants will be used for working capital and general corporate purposes.

• Recent offerings and warrant exercises have been used to fund operations and development activities.